MedTrace Logo

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

NCT02923531 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-12-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab but not exhibiting a radiological response.

Conditions

Interventions

DRUG

X4P-001

X4P-001 will be administered as per the dose and schedule specified in the arm.

DRUG

Nivolumab

Nivolumab will be administered as per the dose and schedule specified in the arm.

Sponsors & Collaborators

  • X4 Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · X4 Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-07
Primary Completion
2018-08-08
Completion
2018-08-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02923531 on ClinicalTrials.gov